Lund, July 8, 2021 – Active Biotech (Nasdaq Stockholm: ACTI) today announced that its partner in the naptumomab project, NeoTX, will host a thought leader (KOL) webinar on combating resistance to inhibitors of checkpoints on Wednesday July 14.^e at 10 a.m. Eastern Time (ET)

The webinar will include a presentation by KOL Mario Sznol, MD, Yale Cancer Center, who will discuss New Frontiers for Checkpoint Inhibitors in Immuno-Oncology. NeoTX management will also give an update on their Tumor Targeted Superantigen (TTS) lead platform candidate naptumomab estafenatox (naptumomab) to overcome resistance. Naptumomab is being evaluated in combination with chemotherapy, checkpoint inhibitors and CAR T. Dr. Sznol and NeoTX management will be available to answer questions after the formal presentations.

See also neotx.com/press-releases for NeoTX communication and for event registration.

Since 2016, Active Biotech has a license agreement with NeoTX Therapeutics Ltd. for the development and worldwide commercialization of naptumomab for the treatment of cancer.

For more information, please contact:
Hélène Tuvesson, CEO, +46 46 19 21 56, [email protected]
Hans Kolam, CFO, +46 46 19 20 44, [email protected]

This information has been submitted for publication, through the contact person indicated above, at 8:30 a.m. CET on July 8, 2021.

Active biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company deploying its extensive knowledge base and portfolio of compounds to develop first-class immunomodulatory therapies for specialized oncology and immunology indications with medical need high unsatisfied and a large commercial market. potential. Following a refocusing of the portfolio, Active Biotech’s economic model aims to advance projects until the clinical development phase and then to further develop programs internally or to continue in partnership. Active Biotech currently has three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, in partnership with NeoTX Therapeutics, is in a phase Ib / II clinical program in patients with advanced solid tumors. The small molecule immunomodulators tasquinimod and laquinimod, both having a mode of action that includes modulating myeloid immune cell function, target hematologic malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib / IIa for the treatment of multiple myeloma. Laquinimod moves into phase II for the treatment of non-infectious uveitis in the second half of 2021. Please visit www.

Active Biotech AB

(Company Reg.No. 556223-9227)
Scheelevägen 22, SE-223 63 Lund, Sweden
Phone: +46 (0) 46 19 20 00

Attachment